Clinical research on post-COVID launched
In recent weeks, the first participants have begun in the RECLAIM Study. The RECLAIM study is a platform trial focused on post-COVID, with the main goal of identifying effective and safe medications for patients suffering from post-COVID.
Special attention is given to drugs that are already on the market for other diseases. Currently, the effects of the medications metformin and colchicine are being compared to standard care.
The RECLAIM study is being conducted entirely remotely, allowing adult patients from all over the Netherlands to participate.
The focus is on patients with persistent fatigue and/or post-exertional malaise (PEM) following a COVID infection. Participants in the study will use the medications for three months and will be followed up for six months through questionnaires and conversations with the research team.
The RECLAIM study is coordinated by Prof. Dr. Janneke van de Wijgert from UMC Utrecht, in collaboration with Ecraid. Both organisations are part of a larger consortium - the Post-COVID Network Netherlands (PCNN). PCNN is a national partnership in which patients, scientists, healthcare professionals, and societal partners work together to align scientific research and patient care for people with post-COVID.
Patients who wish to participate must register in the PCNN patient portal: postCovid Onderzoek.
For more information, please visit: www.postcovidnet.nl